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Low Serum Alpha-1 Antitrypsin (AAT) in Family Members 
of Individuals with Autism Correlates with PiMZ Genotype
Abstract
Aim: Deﬁ  ciency of Alpha-1-antitrypsin (AAT) can be a genetic condition that increases the risk of developing liver, lung 
and possibly gastrointestinal disease. Since many autistic children also have gastrointestinal disorders, this study was designed 
to measure serum concentration of AAT and establish AAT genotypes in autistic children, age and gender matched non-
autistic siblings, parents and controls.
Subjects and Methods: We used an indirect ELISA with monoclonal IgG to AAT to measure AAT serum concentrations 
in 71 members from 16 families of individuals with autism and 18 controls (no family history of autism). We used a duplex 
polymerase chain reaction to detect M, S and Z alleles for alpha-1 antitrypsin expression in 52 members of 12 of the above 
families.
Results: A signiﬁ  cantly high number of autistic family members had lower than normal serum levels of AAT when compared 
to controls. Autistic children with regressive onset had signiﬁ  cantly lower levels of AAT compared to controls, and a 
signiﬁ  cant number of autistic children with low serum AAT also had hyperbilirubinemia, gastrointestinal disease and 
respiratory problems. We also found that a signiﬁ  cantly high number of these individuals had the PiMZ genotype and 
correspondingly low levels of serum alpha-1 antitrypsin.
Discussion: Knowing that low levels of alpha-1 antitrypsin may be inherited, and that low levels of AAT may be associated 
with GI disease in autistic children, genotyping autistic children may help identify individuals susceptible to developing 
digestive problems.
Keywords: alpha-1 antitrypsin, autism, gastrointestinal disease
Introduction
Alpha-1-antitrypsin (AAT) is the most abundant circulating serine protease inhibitor with normal serum 
concentration of 85–250 mg/dL, but peak concentrations as great as fourfold that of normal may occur 
during inﬂ  ammation.
1–3 AAT is a 394 amino acid, 52 kDa glycoprotein synthesized in the liver and 
secreted into the circulation with a half-life of 4–5 days.
3
AAT deﬁ  ciency is a genetic condition that increases the risk of developing a variety of diseases 
including pulmonary emphysema, cirrhosis of the liver and possibly GI disease. It is caused by mutations 
in the AAT gene coding
4–6 on the long arm of human chromosome 14 (locus 14q32.1).
7 Over 100 allelic 
variants of this gene have been identiﬁ  ed and 34 of them have been associated with a quantitative or 
functional deﬁ  ciency of circulating AAT.
8
The protease inhibitor or Pi system has been used to name the various mutations of the AAT gene.
9 
The normal allele is Pi M and the classic severe deﬁ  ciency is associated with the Pi Z allele. Individuals 
with the recessive Pi ZZ genotype tend to have circulating levels of AAT, which are 10%–15% of 
individuals with the Pi MM genotype.
10 Since the alleles are co-dominant, heterozygotes (PiMZ) have 
values approximately 35% of the normal concentration. Other genotypes associated with severe deﬁ  ciency 
include Pi SZ, Pi Z/Null and Pi Null, as well as an array of much more rare Pi types.
1–11 The population 
prevalence for the MM, MS, and MZ genotypes among whites are 86, 9, and 3%, respectively.
12
Alpha-1 antitrypsin (AAT) is mostly secreted by hepatocytes and, to a lesser extent, by lung epithelial 
cells and phagocytes. It inhibits a variety of serine proteinases, but its preferred target is human neutrophil 
elastase (HNE), for which it demonstrates the highest afﬁ  nity.
13
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The major function of AAT in the lungs is to 
protect the connective tissue from HNE released 
from triggered neutrophils, as supported by the 
development of pulmonary emphysema early in 
life in subjects affected by severe inherited 
deﬁ  ciency of AAT.
14 In the majority of humans, 
the lungs are defended from HNE attack by normal 
AAT plasma levels ranging from 85 to 250 mg/dl.
15 
Although AAT is a well-known acute phase 
reactant, this wide variability in its normal plasma 
level mostly reﬂ  ects the marked pleomorphism of 
the glycoprotein. More than 100 genetic variants 
of AAT have been identiﬁ  ed and these are strictly 
associated with speciﬁ  c AAT plasma levels in a 
co-dominantly inherited fashion.
16–17
Alpha-1 antitrypsin production increases mark-
edly after stresses such as surgery, injury, infection, 
or inﬂ  ammation and with estrogen administration.
3 
Low values are associated with emphysema, liver 
disease and possibly gastrointestinal disease.
18
Toxic chemicals found in cigarette smoke, air 
pollutants, oxidizing chemicals, and oxidizing 
agents released by activated neutrophils, all inac-
tivate a critical portion of the alpha-1-antitrypsin 
molecule.
19
If autistic children express low levels of alpha-
1-antitrypsin.
20 they may be more susceptible to 
proteolytic damage caused excess digestive 
enzymes released from white blood cells during 
inﬂ  ammation or infection.
21
Children with autism frequently have nongastro-
intestinal symptoms suggestive of digestive diseased, 
such as reﬂ  ux esophagitis.
22 Infants and children 
with gastroesophageal reﬂ  ux disease more frequently 
have sleep disturbance than the normal population.
23 
Autistic children also have functional gastrointesti-
nal abnormalities. Low activities of disaccharidase 
enzymes (lactase, maltase, sucrase, palatinase, and 
glucoamylase) have been found in autistic children.
22 
Abnormal serum liver function tests have been 
described in children with AD.
24–25 Wakeﬁ  eld et al.
26 
obtained ileocolonic biopsies from 60 consecutive 
children with developmental disorders, 83% of 
whom had autism. Fifty-nine had one or more GI 
symptoms (e.g. abdominal pain, constipation, diar-
rhea, changing stool consistency [constipation 
alternating with diarrhea], or bloating. All were well 
nourished with height and weight within the normal 
range. Colonic endoscopic ﬁ  ndings included seg-
mental swelling, hyperemia, superﬁ  cial erosions, 
and nodularity. On histologic examination, mild to 
moderate ileal lymphoid nodular hyperplasia (LNH) 
was described in 93% of the developmentally 
delayed and autistic children examined.
Since some autistic children have GI problems 
which might be associated with inﬂ  ammation, we 
hypothesized that low AAT levels may be associ-
ated with these conditions.
In this study, we determined AAT serum concen-
trations of 71 members from 16 families of indi-
viduals with autism, compared these to concentrations 
of AAT in 18 controls (parents with no family history 
of autism), and found that a signiﬁ  cant number of 
family members had lower than normal AAT levels 
(less that 85 mg/dl). Using a duplex polymerase 
chain reaction, we detected M, S and Z alleles for 
alpha-1 antitrypsin expression in 52 family members 
from 12 of the above families. We found a signiﬁ  -
cantly high number of family members (n = 37) with 
the MZ genotype. A signiﬁ  cant number of these 
heterozygotes also had correspondingly low levels 
of serum alpha-1 antitrypsin.
Since AAT concentration may be lower than 
that of the normal population, detection of low 
serum AAT and establishment of AAT genotype, 
might be useful tools for assessing prognosis in 
autism. Also, a better understanding of the inci-
dence of AAT deﬁ  ciency in autistic families and 
its potential relationship to gastrointestinal, liver 
and lung diseases, may lead to better therapy.
Methods
We used an indirect ELISA and western blotting, 
as previously described
27,28 to quantitate AAT 
concentration in serum of autistic and control 
individuals. We also used a duplex polymerase 
chain reaction to detect M, S and Z alleles for 
alpha-1 antitrypsin expression.
29
Indirect ELISA to quantitate 
the concentration of serum AAT
Puriﬁ  ed Alpha-1 antitrypsin (Sigma) at concentrations 
of 1 μg, 0.1μg, 0.01 μg and 0.001 μg per 100 μl of 
bicarbonate buffer (pH 9.6), and 100 μl serum protein 
at a dilution of 1:500 (PBS), were ﬁ  xed to wells of 
96 well polystyrene microculture plate (Corning) by 
incubation overnight at 4 degrees C. Excess AAT/
serum was dumped from wells, and all wells were 
blocked by washing 3X with 300 μl blocking solution 
(Superblock, Pierce). One hundred microliters of   
primary antibody (mouse Mab to AAT (Biomedia), 
diluted 1:500 with PBS, was added to all wells and 
plate was incubated for 2 hours at 37 degrees C. 47
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All wells were washed 3 times with PBS/tween. One 
hundred microliters of afﬁ  nity puriﬁ  ed alkaline phos-
photase conjugated goat anti mouse IgG (Biorad), 
diluted 1:5000 with PBS, were added to all wells and 
incubated for 45 minutes at 37 degrees C. All wells 
were washed 5 times with PBS/tween. One hundred 
microliters of AP substrate (Biorad) were added to all 
wells and the plate was incubated at room temperature 
until signiﬁ  cant color change in positive control 
(10–15 minutes). Optical density was measured using 
ELISA Reader (Biorad).
Western blot to test speciﬁ  city 
of monoclonal anti-AAT IgG 
to puriﬁ  ed AAT
Protein Preparation
Puriﬁ  ed AAT (Sigma), and controls were incubated 
1:1 with loading dye (with beta mercaptoethanol) 
at 95 C for 5 minutes. Protein was run on SDS-Page 
(18%) (BioRad), at 100 volts, 1 μg/lane.
Blot
Proteins were transferred to nitrocellulose at 30 volts, 
overnight at 4 C. Nitrocellulose was ﬂ  ooded with 
blocking solution (1% casein/PBS) and rocked 
gently overnight.
Immunoblot
Ten ml of primary antibody (mouse Mab to AAT 
diluted 1:500 with PBS; Negative control—PBS) 
was ﬂ  ooded over appropriate nitrocellulose sheets 
and incubated for 2 hours at room temperature with 
gentle rocking. Sheets were washed 3 times using 
PBS/tween. Five minutes for each wash, rocking 
gently at room temperature. Sheets were ﬂ  ooded 
with 10 ml of afﬁ  nity puriﬁ  ed goat anti-mouse IgG 
conjugated with Horse Radish Peroxidase (HrP) 
(Biorad), diluted 1:5000 with PBS. Sheets were 
washed 5 times with PBS/tween, ﬁ  ve minutes each 
wash, rocking gently at room temperature. Sheets 
were ﬂ  ooded with 10 ml of HrP substrate at room 
temperature until signiﬁ  cant color change.
Genotyping of autistic and nonautistic 
family members using pcr 
and restriction enzyme analysis
Polymerase chain reactions was performed with 
standard buffer (0⋅1 μ Tris-HCl, pH = 8⋅3, 0⋅5 μ 
KCl and 10 mμ MgCl2). in a total volume of 100 μl 
containing: 250 ng of genomic DNA, 0⋅25 pM each 
of the oligonucleotide primers, 0⋅2 mμ of dNTPs 
and 2⋅5 U of Taq polymerase. Primers used 
11 detecting the S mutation are: 5′-TGAGGGGAAAC-
TACAGCACCTCG-3′ and 5′AGGTGT-
GGGCAGCTTCTTGGTCA-3′; primers detecting 
the Z mutation are: 5′-ATAAGGCTGTGCTGAC-
CATCGTC-3′ and 5′-TTGGGTGGGATTCAC-
CACTTTTC-3′. Temperature cycling conditions 
were: initial 10 min denaturation at 94 °C, 30 cycles 
of 2 min at 94 °C, annealing for 2 min at 55 °C, 
extension for 3 min at 72 °C, and ﬁ  nal extension for 
10 min at 72 °C. Twenty microlitres of ampliﬁ  cation 
product were digested for 3 h at 65 °C in a 50 μl 
volume containing 20 U of TaqI restriction enzyme, 
in the appropriate buffer. The digested DNA was 
electrophoresed in a 3% agarose minigel for 3 h at 
90 volts, stained with ethidium bromide and visual-
ized under 254 nμ uv trans-illumination.
Patient group
Seventy-one family members from 16 families of 
individuals with autism, obtained from the Autism 
Genetic Resource Exchange (AGRE, see below), 
and 18 controls (parents with no family history of 
autism), obtained from National Disease Research 
Interchange (NDRI, see below) were tested for 
their serum concentration of alpha-1 antitrypsin 
and AAT genotype.
Results
AAT concentration
Using an indirect ELISA, serum from individuals 
was tested using anti-AAT monoclonal IgG and 
compared to varying concentrations (1 μg–0.001 μg/) 
of puriﬁ  ed AAT and negative control (PBS). Spec-
iﬁ  city of monoclonal anti-AAT IgG was established 
using western blotting (Fig. 1). Results of a typical 
ELISA are shown on Figure 2.
Forty-ﬁ  ve of the 71 individuals from the 16 families 
had AAT concentrations less than 85 mg/dL serum, 
making them low producing individuals (Table 1). 
Whereas none of the 18 non-autistic controls had levels 
of AAT less than 85 mg/dL (Fig. 3) (p   0.05).
Comparing AAT levels in parents and autistic 
children with a variety of demographics (Fig. 4 
and Table 2), a signiﬁ  cantly high number of autistic 
family members (45/72) had lower than normal 48
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levels of AAT when compared to controls (0/18) 
(p   0.01). Of the types of autistics tested, we found 
that non verbal (11) and non verbal regressive (8), 
autistic siblings had signiﬁ  cantly lower levels of 
AAT compared to controls (13) (p   0.05).
Using medical history reports (gathered by 
AGRE), we analyzed the phenotypic characteriza-
tion of the probands of family members tested in this 
study (Table 2). Overall, twenty-seven autistic chil-
dren were tested for AAT concentration. Questions 
associated with hyperbilirubinemia were not 
answered for ﬁ  ve of these children. Of the 22 remain-
ing, 8 had hyperbilirubinemia at birth (36%). This is 
signiﬁ  cantly higher than the expected 6 percent of 
normal children who have the disorder. Six of the 
remaining 8 with hyperbilirubinemia had low levels 
of AAT (less than 85 mg/dL) (p   0.05). Two of the 
8 with hyperbilirubinemia required phototherapy.
Three of the 23 affected individuals who 
answered the related questions had respiratory 
distress syndrome (RDS) (p   0.05). Two of these 
three were born after short gestation (29 weeks). 
All three required oxygen supplimentation. None 
of these individuals had hyperbilirubinemia. Two 
of these three had deﬁ  cient levels of AAT.
Six other affected siblings (not including the 
three with RDS) reported respiratory problems later 
in life. Five of these 6 had deﬁ  cient levels of AAT. 
SDS-PAGE and Wedtern Blot Showing Specificity of Monoclonal Antibody to Alpha-1 Antitryspin
1. Serum
2. Thyroxin Binding Globin (TBG)
3. Alpha-1 Antitrypsin (AAT)
4. Standards
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7. Monoclonal lgG to AAT
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Table 1.
Diagnosis Sex Twins Relationship AAT
mg/dL
Genotype
Family 1 F Parent 95
M Parent 54
Asp M Sibling 58
AR M IT Sibling 49
A M IT Sibling 47
Family 2 F Parent 45
M Parent
AR M Sibling 51
AR M Sibling 54
NA F Sibling 44
Family 3 F Parent 22 MZ
M Parent 24 MZ
AR F FT Sibling 38 MZ/Null
PDD M FT Sibling 46 MZ
Family 4 F Parent 54
M Parent 65
NA M Sibling 61
A F Sibling 73
A F Sibling 45
Family 5 PDD M Sibling 176
AR M Sibling 100
M Parent 72
M Parent 74
PDD F Sibling 76
Family 6 M Parent 126 MZ
A M Sibling 123 MM
PDD F Sibling 86 MZ
A M Sibling 78 MZ
F Parent 141 MM
Family 7 A M Sibling 93
A M Sibling 133 MM
F Parent 88 MZ
M Parent 117 MM
Family 8 F Parent 124 MZ
M Parent 104 SZ
PDD M FT Sibling 78 MZ
A F FT Sibling 70 SZ
NA M Sibling 146 MZ
NA M Sibling 68 SZ
(Continued)50
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Table 1. (Continued)
Diagnosis Sex Twins Relationship AAT
mg/dL
Genotype
Family 9 NA F Parent 146 MM
NA M Parent 214 MM
PDD M Sibling 89 MM
NA F Sibling 197 MM
AR M Sibling
Family 10 NA F Parent 97 SZ
NA M Parent 94 MZ
A F Sibling 55 MZ
A M IT Sibling 129 MS
A M IT Sibling 100 MS
Family 11 NA F Parent 46 MZ
NA M Parent 51 MZ
AR F Sibling 29 MZ
AR M Sibling 18 MZ
Family 12 A F Sibling 84 MZ
NA F Parent 84 MZ/ZZ
Asp M Sibling 53 MZ
NA M Parent 88 MZ
Family 13 NA F Parent 54 MZ
NA M Parent 23 MZ/ZZ
A M Sibling 15 MZ
A M Sibling 35 MZ
Family 14 NA F Parent 82 MZ/SZ
NA M Parent 92 MZ
AR M Sibling 36 MZ
AR F Sibling 31 MZ
Family 15 NA F Parent 50 MZ
NA M Parent
NA F Sibling 49 MZ
AR M FT Sibling 51 MZ
A M FT Sibling 51 MZ
Family 16 NA F Parent 171 MM
NA M Parent 93 MZ
AR M Sibling 51 MZ
A M Sibling 57 MZ51
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Figure 3.
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Table 2.
Diagnosis Sex Twins Relationship AAT Genotype HB HB RX RD O2 GI GI T
1 mg/dL
2 AR M IT Sibling 49 0 −1 000−1
3 A M IT Sibling 47 0 −1 000−1
4 AR F FT Sibling 38 MZ/Null 1 −1 0 −1 0 −1
5 PDD M FT Sibling 46 MZ 1 −1 00 −1 −1
6 PDD M Sibling 176 0 −1 000−1
7 AR M Sibling 100 1 −1 0 0 1 5,6
8 PDD F Sibling 76 0 −1 000−1
9 A M Sibling 123 MM 0 −1 0 −1 0 −1
10 PDD F Sibling 86 MZ −1 −1 −1 −1 0 −1
11 A M Sibling 78 MZ 1 1 0 0 0 −1
12 A M Sibling 93 MM/MZ 0 −1 000−1
13 A M Sibling 133 MM 1 1 0 0 0 −1
14 PDD M Sibling 89 MM 0 −1 000−1
15 A F Sibling 55 MZ 0 −1 11 −1 −1
16 A M IT Sibling 129 MS 0 −1 11 −1 −1
17 A M IT Sibling 100 MS −1 −1 −1 −1 −1 −1
18 AR M Sibling 1 PT 0 0 1 5
19 AR F Sibling 29 MZ −1 −1 −1 −1 1 887
20 AR M Sibling 18 MZ −1 −1 −1 −1 16
21 A F Sibling 84 MZ 1 PT 0 0 1 5
22 Asp M Sibling 53 MZ 0 −1 0016
23 A M Sibling 15 MZ 1 1 0 0 0 −1
24 A M Sibling 35 MZ 0 −1 000−1
25 AR M FT Sibling 51 MZ −1 −1 11 −1 −1
25 A M FT Sibling 51 MZ 1 −1 000−1
27 AR M Sibling 51 MZ 0 −1 0015
28 A M Sibling 57 MZ 0 −1 000−1
Key
Hyperbilirubinemia and Respiratory History
Select Value Stored Value Answer Text
No 0 No
Yes 1 Yes
N/A 9 N/A
Blank −1 Indicates that no response was entered on 
the collection form/instrument for this 
question
HB—Hyperbilirubinemia
HB-RX—Hyperbilirubinemia Therapy
PT—Phototherapy
RD—Respiratory Distress
O2—Oxygen Suppliment
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Table 2. (Continued)
GI History
Gastroesophageal Reﬂ  ux (Ger) 1
Peptic Ulcer Disease (Pud) 2
Irritable Bowel Syndrome (Ibs) 3
Inﬂ  ammatory Bowel Dis. (Ibd) 4
Chronic Diarrhea 5
Constipation 6
Other 887
Unknown 888
Multiple 889
GI—Gastrointestinal Problem(s)
GI T—Gastrointestinal Problem Type
GI D—Gastrointestinal Problem Description
Although none of the individuals had emphysema, 
two reported multiple respiratory problems—
tracheomalacia and sleep apnea, stridor and laryn-
gomalacia. One reported reactive airway disease. 
One reported multiple incidences of pneumonia and 
the other two did not report a speciﬁ  c disorder.
Seven of 22 affected siblings reported gastro-
intestinal problems. One of these did not answer 
the question. Five of the remaining six had deﬁ  cient 
levels of AAT (p   0.05). Three of the six reported 
chronic diarrhea, one reported constipation, one 
colic and the other, projectile vomiting.
Genotyping
If we predicted the genotype of all 71 members of 
the 16 autistic families based on their AAT serum 
concentrations (Table 1), most (43/71) would be 
heterozygous (30–85 mg/dL). This is signiﬁ  cantly 
higher than the expected 3% in the general popula-
tion. Two pairs of identical twins and three pairs 
of fraternal twins had very similar AAT concentra-
tions and the same predicted genotypes. In ﬁ  ve of 
six families, when parents had deﬁ  cient levels of 
serum AAT (less than 85 mg/dL), all their chil-
dren were deficient. When both parents were 
heterozygous, all their children were heterozygous 
or normal. These ﬁ  ndings suggest an inheritance 
pattern of this trait in these autistic families.
Using a PCR/Restriction Digest we genotyped 
52 members from 12 of the 15 families who had 
been measured for serum AAT concentration (above) 
(DNA was not available for three of the families). 
Expected product demonstrating speciﬁ  c MM, MS, 
SS, MZ and ZZ genotypes for AAT expression is 
shown in Figure 5. The results of a typical assay 
(family 64–69) are shown in Figure 6. In this assay, 
the gel photo shows uncut and cut product for each 
family member and corresponding genotype.
A signiﬁ  cantly high number of family members 
(37) had the MZ genotype. A signiﬁ  cant number 
of these heterozygotes (35 of 37) had correspond-
ingly low levels of serum alpha-1 antitrypsin (less 
than 100 mg/dL) (Table 1).
Discussion
Approximately 75 allelic variants have been described 
in the AAT gene locus resulting in a very complex 
Polymerase chain reaction (PCR) products
before (1) and after (2) Taql restyriction
for the different genotypes. Fragment sizes
are indicated on the left (157, 121, 100 bp)
and the right (179, 157, 100 bp) of the gels;
D: Size markers
Genotypes
MM: 157-100 bp
MS: 157-121-100 bp
SS: 157-121 bp
MZ: 179-157-100 bp
ZZ: 179-100 bp
MM MS SS MZ ZZ
157
121
100
179
157
100
1–2 D 1–2 D 1–2 1–2 1–2
Figure 5.54
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genetic classiﬁ  cation based upon the phenotypic 
features of the circulating AAT protein. The most 
common variant, PI M, is present in approximately 
95% of the Caucasian U.S. population and is 
regarded as the normal variant associated with 
normal serum levels of functional AAT. The pre-
dominant deﬁ  ciency alleles, such as PI Z and PI S, 
may result in decreased levels of circulating AAT 
but with completely normal functioning proteins. 
The MM phenotype is therefore designated as 
manifesting 100% concentration of circulating 
AAT (85–250 mg/dL). The heterozygous combina-
tions MZ and MS yield 35% and the ZZ allele 
10%–25% of this normal MM value. Approxi-
mately 95% of all AAT deﬁ  ciency states leading 
to clinical manifestations are made up of PI ZZ 
homozygotes. Certain alleles, such as the S allele, 
either in the homozygous state or associated with 
the M allele, do not appear to be associated with 
the abnormally polymerized molecules within the 
endoplasmic reticulum and have not been incrim-
inated in the development of liver disease unless 
combined with the Z allele.
14,30
The association of AAT deﬁ  ciency and liver 
disease in children was ﬁ  rst described in 1969.
31 
Many subsequent clinical studies 
32,18 have observed 
that liver disease occurrence in AAT deﬁ  ciency is 
bimodal, affecting children in neonatal life or early 
infancy and, less commonly, adults in late middle 
life. However, only 10% of deﬁ  cient newborns 
develop persistent cholestasis during the ﬁ  rst year 
of life and many of these infants appear to undergo 
a spontaneous remission, with only about 3% of 
the originally diagnosed neonates progress to 
ﬁ  brosis or cirrhosis during childhood and teenage 
years. Nevertheless, careful surveillance revealed 
that many of these have persistently abnormal liver 
enzymes.
30,31
Cederlund and Gillberg (2004),
33 reported neonatal 
hyperbilirubinemia in 22 of 100 boys with Asperger 
syndrome. Bilirubin gets into neurons only if the 
blood-brain barrier is disrupted by some other 
factor.
34,35 Some of the newborns with AAT deﬁ  -
ciency, who develop jaundice, may suffer anoxia 
or sepsis in the perinatal period, and may therefore 
be at risk for bilirubin crossing the blood-brain 
barrier. Our data shows a signiﬁ  cant relationship 
between low AAT levels and neonatal hyperbili-
rubinemia in autistic children.
Asperger ﬁ  rst recorded the link between celiac 
disease and behavioral psychoses
36 Walker-Smith 
and colleagues detected low concentrations of 
alpha-1 antitrypsin in a small group of children with 
typical autism,
20 and D’Eufemia and colleagues 
identiﬁ  ed abnormal intestinal permeability, a feature 
of small intestinal enteropathy, in 43% of a group of 
autistic children with no gastrointestinal symptoms, 
but not in matched controls.
37 Some have also found 
a relationship between chronic enterocolitis and 
regressive developmental disorder.
38 These studies 
and evidence of anemia and immune deﬁ  ciency in 
some autistic children, suggest an association 
between intestinal dysfunction and autism spectrum 
disorders (ASD). However, increased incidence of 
gastrointestinal problems in autistic children is still 
under study because the exact relationship between 
GI symptoms and ASD is unclear.
39 Our data, how-
ever, suggests that a high number of autistic children 
with low levels of AAT may also have gastrointes-
tinal problems, especially diarrhea.
In inﬂ  ammatory conditions, AAT levels are 
normally elevated. In this study, however, the 
results demonstrate low alpha-1-antitrypsin serum 
levels, which are probably due to genetic factors 
and not excess protein loss in stool. This might 
contradict the theory that autistic patients have 
64 - Male Parent - MZ 
65 - Female Parent - SZ
66 - Child/M/PPD Non Verbal Fraternal Twin - MZ
67 - Child/F/Autistic Non Verbal Fraternal Twin - SZ
68 - Child/M/Non Autistic - MZ
69 - Child/M/Non Autistic - SZ
64C 64U 65C 65U 66C 66U  C
200
bp
100
67C 67U 68C 68U 69C 69U  C
Figure 6.55
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inﬂ  ammatory bowel disease because if there was 
chronic inﬂ  ammation due to enterocolitis, the alpha-
1-antitrypsin level should be elevated. However, 
there is evidence that increased inﬂ  ammation is 
associated with AAT deﬁ  ciency, such as GI inﬂ  am-
mation in patients with ulcerative colitis, associated 
with the PiZ carriers,
40 and neutrophil associated 
inﬂ  ammation seen in the lungs of AAT deﬁ  cient 
patients.
41 Also, PiMZ subjects without airﬂ  ow 
obstruction may have an IL-8 related neutrophilic 
inﬂ  ammation in the pulmonary airways 
42 and they 
are more likely to develop both liver (cirrhosis or 
ﬁ  brosis) and lung disease (emphysema).
43
In this preliminary study, a signiﬁ  cant number 
of autistic family members have low serum levels 
of AAT, which is, at least in part, caused by the 
PiMZ genotype. Low serum AAT in autistic chil-
dren supports the ﬁ  ndings of Walker-Smith and 
colleagues, and strongly suggests an association 
between autism and AAT deﬁ  ciency.
A high number of autistic children with low 
levels of AAT in our study, also had neonatal 
hyperbilirubinemia (8/22), respiratory problems 
(9/23) and digestive disorders (7/22). Since AAT 
deﬁ  ciency may be associated with these problems, 
this also supports our hypothesis of an association 
between AAT deﬁ  ciency and autism.
Our study also suggests an association between 
autistic children with regressive disease and AAT 
deﬁ  ciency. This suggests that, besides genetic 
predisposition, environmental factors may be inﬂ  u-
encing levels of serum AAT in these individuals.
Our observation, however, that some non-autistic 
siblings inherit AAT deﬁ  ciency, and parents of 
autistic children who also have low levels of serum 
AAT, suggests that AAT deﬁ  ciency alone is not a 
causative agent for ASD, but may make a subset of 
autistics susceptible to inﬂ  ammatory disease.
Knowing that low levels of alpha-1 antitrypsin 
is inherited, and that low levels of AAT may be 
associated with GI disease, genotyping autistic 
children may help identify those autistics suscep-
tible to developing digestive problems. And a 
better understanding of the incidence of AAT deﬁ  -
ciency in autistic families and its potential relation-
ship to liver, lung and bowel diseases, may lead to 
better therapeutic strategies.
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